Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cidara Thera Cmn (CDTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 113,468
  • Shares Outstanding, K 16,810
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,170 K
  • 36-Month Beta 1.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.60 +2.27%
on 05/24/17
8.02 -15.84%
on 04/27/17
-0.95 (-12.34%)
since 04/26/17
3-Month
6.10 +10.66%
on 04/20/17
8.02 -15.84%
on 04/27/17
-0.80 (-10.60%)
since 02/24/17
52-Week
6.10 +10.66%
on 04/20/17
12.95 -47.88%
on 09/19/16
-4.48 (-39.89%)
since 05/26/16

Most Recent Stories

More News
Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2017 and...

CDTX : 6.75 (+0.75%)
Is a Surprise Coming for Cidara Therapeutics (CDTX) This Earnings Season?

Cidara Therapeutics (CDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into this earnings season.

CDTX : 6.75 (+0.75%)
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

AUPH : 6.36 (-3.49%)
CDTX : 6.75 (+0.75%)
EDIT : 15.62 (-4.23%)
PRGO : 69.95 (-2.64%)
What's in Store for BioDelivery (BDSI) this Earnings Season?

BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.

ENDP : 13.12 (+1.78%)
BDSI : 2.40 (+9.09%)
CDTX : 6.75 (+0.75%)
EDIT : 15.62 (-4.23%)
What's in the Cards for Ionis (IONS) this Earnings Season?

Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping...

ALQA : 0.38 (unch)
IONS : 46.38 (+0.06%)
CDTX : 6.75 (+0.75%)
BIIB : 250.80 (-0.86%)
Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Taylor Sandison, M.D., M.P.H., has been...

CDTX : 6.75 (+0.75%)
Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from nonclinical studies of its novel...

CDTX : 6.75 (+0.75%)
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

ESPR : 32.83 (-1.35%)
ARGS : 0.46 (+15.00%)
VRTX : 119.92 (+1.11%)
CDTX : 6.75 (+0.75%)
NKTR : 20.79 (-3.30%)
3 of the Best & Worst Performing Drug Stocks of Q1

Here is a look at 3 of the best and worst-performing drug stocks in the first quarter of 2017.

ESPR : 32.83 (-1.35%)
ARGS : 0.46 (+15.00%)
VRTX : 119.92 (+1.11%)
CDTX : 6.75 (+0.75%)
XENE : 4.00 (+1.27%)
NKTR : 20.79 (-3.30%)
Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First Cloudbreak(TM) Antibiotic Immunotherapy

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has received a grant for up...

CDTX : 6.75 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Support & Resistance

2nd Resistance Point 6.88
1st Resistance Point 6.82
Last Price 6.75
1st Support Level 6.67
2nd Support Level 6.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.